Clinical Strategies for the Chemoprevention of Localized Prostate Cancer | Chapter 2 | Medical Science: Recent Advances and Applications Vol. 1

Prostate cancer is a complex, heterogeneous disease that demands concurrent inhibition of multiple hallmark-associated pathways. Prostate cancer is the most common cancer among men in the United States and the second leading cause of cancer-related deaths. Metastatic castration-resistant prostate cancer is still a fatal disease. On the other hand, between 2016 and 2020, about 70% of Prostate cancer cases were diagnosed at a localized stage. Evolving data demonstrate that men with low-grade cancers treated with definitive therapies may now be exposed to morbidities of overtreatment and poor quality of life, with little or no benefit in terms of cancer-specific mortality. Active surveillance is thus the recommended management strategy for men with low-grade disease. Although this subgroup of men has reported anxiety during the AS period, they account to be highly motivated to make positive lifestyle changes to further reduce their risk of prostate cancer progression, underscoring the urgent need to identify novel strategies for preventing progression of localized prostate cancer to metastatic disease through pharmacologic means, an approach termed chemoprevention. Over the past decade, there have been several attempts to identify and evaluate agents and approaches for Prostate cancer chemoprevention targeting healthy men or men at relatively higher risk for Prostate cancer (HGPIN) or early phase trials of short duration in Prostate cancer patients with localized disease during the 4-6 week pre-surgical window (Biopsy to prostatectomy). Several promising agents such as soy isoflavones, lycopene, Selenium, Vitamin E, resveratrol, green tea catechins, and other nutritional approaches have been examined over the past 2 decades. However, currently, there are several limitations in the research approach used to systematically examine these agents and approaches for chemoprevention. Consequently, there are no concrete recommendations that can be provided to men who are on active surveillance to reduce the risk of progression from early to advanced stage of prostate cancer. The goal of this review is to summarize the current agents and approaches evaluated, targeting men on active surveillance, recognize the gaps, and identify a contemporary and comprehensive path forward. Results of these studies may inform the development of well-powered phase III clinical trials and ultimately provide a strategy for clinical chemoprevention in men on active surveillance, for whom, currently, there are no options for reducing the risk of progression to metastatic disease. Early phase trials must include objective markers of compliance with to study agent throughout the trial, in addition to pill counts and self-reported daily study-agent intake logs.

 

Author (s) Details

 

Nimat Alam
Department of Family and Community Medicine, Texas Tech University Health Science Center, USA.

 

Linda Esteban
Department of Family and Community Medicine, Texas Tech University Health Science Center, USA.

 

Enrique Tobias
Department of Family and Community Medicine, Texas Tech University Health Science Center, USA.

 

Jenet George
Department of Family and Community Medicine, Texas Tech University Health Science Center, USA.

 

Please see the book here:- https://doi.org/10.9734/bpi/msraa/v1/4818

Prognostic Validity of DNA Karyometry in Prostate Cancer Patients under Active Surveillance| Chapter 11 | Current Practice in Medical Science Vol.10

 The choice of dynamic reconnaissance for patients with confined prostate disease relies upon a low Gleason score (GS) of 6. By the by, around 30% of patients face clinical movement in five years or less. Our goal was to demonstrate the better prognostic legitimacy of DNA karyometry than foresee non-movement of prostate malignant growth patients under dynamic observation.

 

Our speculation is that robotized estimations of the DNA content of prostate disease cells produce a DNA grade of danger that is considerably more exact than the emotional GS in foreseeing non-movement of prostate malignant growths. Atomic DNA estimations of disease tissue in the remaining biopsy material of 80 patients from the HAROW (chemicals, dynamic reconnaissance, radiation, activity, vigilant pausing) study were taken. Still up in the air by neighborhood pathologists and a reference pathologist. A 4.1 year follow-up included rehashed prostate-explicit antigen (PSA) esteems, the number and GSs of positive biopsies, assurance of the clinical stage, and in 19 cases the consequences of prostatectomies.

Reproducibility of the GSs was 55% without separation between stages 6 and 7a and 45% with separation between stages 6 and 7a. Movement happened in 37.5% of patients in the event that an overhaul of any consideration basis was utilized as proof and in 18.8% of patients if by some stroke of good luck PSA multiplying time (DT) of <36 months or upstaging to arrange pT3 was utilized as proof. The commonness of DNA grade 1 was 40%. Responsiveness, explicitness, and negative prescient worth of nearby pathologists' GSs, the reference pathologist's GSs, and DNA karyometry were 0%, 95.0%, and 74.0%; 20.0%, 86.7%, and 76.5%; and 85.0%, 51.0%, and 90.6% in the event that an overhaul of any consideration standard was utilized as proof of movement and 5.9%, 96.8%, and 79.2%; 23.5%, 87.3%, and 80.9%; and 100 percent, 50.8%, and 100 percent if by some stroke of good luck a PSA DT of <36 months as well as upstaging to organize pT3 were utilized. In this way, contrasted with emotional Gleason scoring, objective computerized DNA karyometry can significantly more reliably preclude the progression of prostate malignancies under dynamic reconnaissance (AS) in four years or less.

For the abstract tiny GS yet 100 percent for true DNA karyometry, the possibility barring dispassionately resolved progression of an untreated, restricted prostate malignant growth under AS was just 80.9 %. Thusly, this moderate, harmless restorative methodology is fundamentally safer for patients with a DNA grade of threat of 1.

Author(s) Details:

Alfred H. Böcking,
Institute of Cytopathology, University of Düsseldorf, Düsseldorf, Germany.

David Friedrich,
Institute of Computer Vision, RWTH Aachen University, Aachen, Germany.

Christof Börgermann,
Department of Urology, City-Hospital, Düren, Germany.

Stefan Biesterfeld,
Section of Cytopathology, University of Düsseldorf, Düsseldorf, Germany.

Rainer Engers,
Center of Pathology, Germany.

Josef Dietz,
Bundesverband Prostatakrebs Selbsthilfe, Stuttgart, Germany.

Please see the link here: https://stm.bookpi.org/CPMS-V10/article/view/8075